|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
In particular, our two-stage strategy found association in both our combined case/control analysis and the family-based analysis on 1q21.2 (closest gene: sphingosine-1-phosphate receptor 1 gene, S1PR1) and on 1q24.1 near the gene TMCO1, and at CSMD1 on 8p23.2, supporting several previous GWAS reports for BD and for schizophrenia.
|
24387768 |
2014 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
In particular, our two-stage strategy found association in both our combined case/control analysis and the family-based analysis on 1q21.2 (closest gene: sphingosine-1-phosphate receptor 1 gene, S1PR1) and on 1q24.1 near the gene TMCO1, and at CSMD1 on 8p23.2, supporting several previous GWAS reports for BD and for schizophrenia.
|
24387768 |
2014 |
|
Neointima
|
0.300 |
Biomarker
|
disease |
CTD_human |
Angiotensin II facilitates neointimal formation by increasing vascular smooth muscle cell migration: Involvement of APE/Ref-1-mediated overexpression of sphingosine-1-phosphate receptor 1.
|
29609002 |
2018 |
|
Neointima Formation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
These findings demonstrate that Ang II stimulates the epigenetic regulation of S1PR1 expression via H<sub>2</sub>O<sub>2</sub>-mediated APE/Ref-1 translocation, which may consequently be involved in Ang II-induced VSMC migration and vascular neointima formation.
|
29609002 |
2018 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Carcinoma, Spindle-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Carcinomatosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Mammary Carcinoma, Animal
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Hypertensive disease
|
0.210 |
Biomarker
|
group |
BEFREE |
Our study identifies S1P-S1PR1-nitric oxide signaling as a new regulatory pathway in vivo of vascular relaxation to flow and BP homeostasis, providing a novel therapeutic target for the treatment of hypertension.
|
28607130 |
2017 |
|
Hypertensive disease
|
0.210 |
ModifyingMutation
|
group |
RGD |
This region contains several physiological candidate genes for salt-sensitive hypertension in the SHRSP, including Edg1 and Vcam1, which are differentially expressed and lie on common and functionally important pathways.
|
17938382 |
2007 |
|
Cardiomegaly
|
0.200 |
Biomarker
|
phenotype |
RGD |
EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes.
|
11549339 |
2001 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The S1PR1 functional antagonist FTY720 (Gilenya) is FDA-approved for treating multiple sclerosis, and selective A3AR agonists are in advanced clinical trials for cancer and inflammatory disorders, underscoring the need for their expedited trials in patients with CINP as chemotherapy adjuncts.
|
31490328 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression pattern of S1PR subtypes (S1PR1-S1PR5) may alter in cancer development stages, depending on the origin and the pathologic features of tumors.
|
30712233 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blot assay was used to evaluate S1PR1 and p-STAT3 expression in MDSCs after separation from the liver and tumor by magnetic antibody.
|
31534132 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling.
|
31825830 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer.
|
30718502 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that fingolimod behaves as an S1PR1 agonist to reduce pain in multiple sclerosis by reversing central sensitization of spinal nociceptive neurons.
|
29140922 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 is an approved drug for multiple sclerosis and acts as a functional antagonist for S1PR1.
|
30083262 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P<sub>1</sub>) to express a variety of symptoms and disease patterns.
|
30409535 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of ApoM could promote NSCLC cell proliferation and invasion in vitro and tumor growth in vivo, which might be via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways.
|
29750961 |
2018 |